



MedStar Family Choice

UPDATE to the MEDSTAR FAMILY CHOICE FORMULARY District of Columbia Healthy Families and Healthcare Alliance July 2017 Pharmacy and Therapeutics Committee Meeting

CHANGES BELOW WILL BECOME EFFECTIVE ON October 1, 2017

Additions:

- AirDuo RespiClick (fluticasone propionate and salmeterol)
- ezetimibe/simvastatin (combination previously branded as Vytorin)

Additions with Prior Authorization:*

- **Ingrezza (valbenazine)** for the treatment of tardive dyskinesia.
- **Zejula (niraparib)** for maintenance treatment of epithelial ovarian, fallopian tube, and primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

**Please see the PA Table on the MFC website for details of the requirements for approval and guidance on submission of clinical information*

Removals:

- None

Removal of Prior Authorization:

- Isotretinoin

Managed Drug Limitations & Step Therapy**

- None

*Details of the Prior Authorization Criteria are on this website in the Prior Authorization Table.

**Details of the Step Therapy Criteria are on this website in the Step Therapy Table.